Podcasts about advances

EVERYONE who signs up wins a FREE toy or gift card!  ⁠⁠https://www.bboutique.co/vibe/emilymorse-podcast Try Timeline today! Text “EMILY” to 57237 and claim your FREE 3-day Trial of Gummies. Your cells will thank you! Magnesium, multiplied. 10 forms for total support. Go to ⁠https://qualialife.com/SEXWITHEMILY⁠ to get 50% off and save an extra 15% with the code SEXWITHEMILY. Sponsored by Je Joue https://www.jejoue.com/products/hera-flex-rabbit-vibrator?utm_source=SWE-HeraFLEXPODCAST&utm_medium=SWE-HeraFLEXPODCAST Join the SmartSX Membership : https://sexwithemily.com/smartsx Access exclusive sex coaching, live expert sessions, community building, and tools to enhance your pleasure and relationships with Dr. Emily Morse. List & Other Sex With Emily Guides: https://sexwithemily.com/guides/ Explore pleasure, deepen connections, and enhance intimacy using these Sex With Emily downloadable guides. SHOP WITH EMILY!: https://bit.ly/3rNSNcZ (free shipping on orders over $99) Want more? Visit the Sex With Emily Website: https://sexwithemily.com/ Episode Description In this Sex with Emily episode, Dr. Emily and producer Erica tackle your trickiest relationship and sex questions—and some of these situations are messier than you think. The wife having sex 5+ times a week who's being pressured to set midnight alarms so her husband can wake her up for more—why this isn't about frequency at all, and the real need he's actually trying to fill. That guy who insists oral sex should only happen "on special occasions" because it gets "taken for granted": what this scarcity mindset reveals about his past relationships, his skill anxiety, or his actual preference—and whether this is a dealbreaker you're discovering early. The biological reason men wake up ready for sex in the middle of the night while their partners are deep asleep—and why disrupting your sleep hygiene to feel "desired" is a Band-Aid on a much deeper issue. When your partner believes doing something too often creates expectations they can't meet: the philosophy problem that shows up in bed and everywhere else, and what "taken for granted" really means about their view on compliments, effort, and intimacy. Why oral sex as foreplay is the norm, not the exception—and how to navigate a partner who sees it as the main event that loses its magic with repetition. Plus: the conversation framework for exploring where your partner's sexual beliefs actually come from, and why the first few months of dating are just data collection on whether you're actually compatible. Timestamps: 0:00 - Introduction 1:01 - Question 1: Rejecting Partner's Advances in the Middle of the Night 6:42 - Understanding Nocturnal Erections and Gender Differences in Arousal 10:10 - Question 2: Feeling Done with a Sexless Marriage After 7 Years 16:20 - Question 3: Getting Upset When Partner Doesn't Want Sex (Mismatched Libidos) 21:28 - Question 4: Dealing with Low Libido and Performance Anxiety at 42 25:10 - Question 5: Wanting Oral Sex Every Time, Not Just Special Occasions 32:52 - Closing Thoughts and How to Connect with Dr. Emily

"Working as an oncology infusion nurse, being oncology certified, attending chapter meetings, going to ONS Congress® has really taught me plenty. But being an oncology patient taught me way more. I know firsthand the fears 'you have cancer' brings. Then going through further testing, CT scans, MRIs, genetics, the whole preparation for surgery was something I never considered when I treated a breast cancer patient," ONS member Catherine Parsons, RN, OCN®, told Valerie Burger, MA, MS, RN, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about her experience being an oncology nurse and cancer survivor. Burger spoke with Parsons and ONS members Margaret Hopkins, MSN, RN, OCN®, HNB-BC, and Afton Dickerson, MSN, AGACNP-BCP, CBCN®, AOCNP®, CGRA, about how cancer survivorship has shaped their careers as oncology nurses and personal lives. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 385: ONS 50th Anniversary: Evolution of Cancer Survivorship Episode 263: Oncology Nursing Storytelling: Renewal Episode 253: The Ethics of Caring for People You Know Personally Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 91: The Seasons of Survivorship ONS Voice articles: Being a Patient Taught Me How to Be a Better Oncology Nurse by Margaret Hopkins Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession Our Unified Voices Can Improve Cancer Survivorship Care Why I Truly Understand How Our Patients Hold Onto Hope ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider ONS Nurse Well-Being Learning Library ONS Huddle Cards: Coping Moral Resilience Survivorship Care Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Parsons: "I thought I knew cancer. I thought I knew the treatment. I thought I knew the side effects. There's so much I didn't know. There's so much behind the scenes before a patient comes and sits in my chair. The stuff that they go through I now can understand. It surprised me how much I didn't know." TS 11:39 Hopkins: "I had been thinking I'm going to be that hero, that I can go to work. I work at night, get 8 am radiation appointments, and go home and go to sleep and wake up and go to work again because everyone said, 'Oh, it's not that bad. Radiation will be okay. You can work.' … But the real challenge for me was I didn't know how to be a patient and a nurse at the same time. And my first radiation treatment, I go in there, and I change into the gown, and then I started cleaning up because I was getting treatment done at the hospital where I worked, and were taught if you see a mess, you clean it. So I was acting like a nurse. And I almost wanted to go help the other patients, but I couldn't because I had to focus on healing." TS 15:36 Dickerson: "What made the difference for me were the nurses who didn't just treat my illness. They treated me as a whole person—my emotions, my feelings. They made me smile. They would hold my hand or just take a moment to really ask, 'Hey, how are you?' And those small, little gestures made me feel worthy, made me feel like a human. I always tell nurses it's not just about the chemo; it's about the connection. Sometimes your presence is the most healing thing that you can offer to your patient." TS 30:52

Advances in quantum computing by 2029 will weaken and break the conventional asymmetric cryptography that underpins many authentication methods, Gartner has warned, significantly reducing their credence and increasing exposure to account takeover risks. The analyst firm's Hype Cycle for Digital Identity 2025 highlights the importance of post-quantum authentication (PQA), also known as quantum-safe authentication, which incorporates post-quantum cryptography to mitigate attacks using quantum computing. You can listen to all of the Quantum Minute episodes at https://QuantumMinute.com. The Quantum Minute is brought to you by Applied Quantum, a leading consultancy and solutions provider specializing in quantum computing, quantum cryptography, quantum communication, and quantum AI. Learn more at https://AppliedQuantum.com.

The Trump administration is aiming to release its six-part national cybersecurity strategy in January, according to multiple sources familiar with the document. The document, which is a mere five pages long, will possibly be followed by an executive order to implement the new strategy. The administration has been soliciting feedback in recent days, which one source considered more of a “messaging” document than anything, with more important work to follow. According to sources familiar with the strategy, the six “pillars” focus on cyber offense and deterrence; aligning regulations to make them more uniform; bolstering the cyber workforce; federal procurement; critical infrastructure protection; and emerging technologies. An opening section of the draft offers a Trumpian call for a more muscular approach to cyberspace. Despite its short length — the Biden administration's cybersecurity strategy was 35 pages long — it touches on a significant number of topics. Those subjects include cybercrime, China, artificial intelligence, post-quantum cryptography and more. A source told CyberScoop the administration appeared genuinely interested in soliciting feedback on the strategy to incorporate or change. The release date of the strategy is fluid. While the administration is targeting January, its publication might follow the broader national security strategy. In other news: Anthropic's Claude for Government is now available across the Department of Health and Human Services, according to an internal announcement obtained by FedScoop. The launch was announced in an email to staff Wednesday from HHS Deputy Secretary Jim O'Neill, and comes two months after the department made ChatGPT available to all of its workers. O'Neill encouraged workers to use either ChatGPT or Claude for their queries or “ask both and compare the responses.” He said in his email: “HHS users can work confidently and securely, with minimal restrictions on the types of information entered, while maintaining full compliance with federal cybersecurity and privacy standards. With this release, we are ensuring that all divisions, programs, and employees have access to two secure cutting-edge AI capabilities.” The email doesn't mention specific contracting details of how HHS is providing access to the tool, but ChatGPT at least was provided through the company's nearly free OneGov deal with the General Services Administration. Anthropic similarly has such a deal with GSA to offer its services to government customers for a nominal fee of $1. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

Interview with Segun Lawson, CEO of Thor Exploration Ltd.Our previous interview: https://www.cruxinvestor.com/posts/thor-exploration-lsethx-nigerian-pioneer-preps-18m-oz-senegal-gold-project-for-q4-pfs-7891Recording date: 3rd December 2025Thor Explorations presents a compelling investment opportunity combining immediate cash generation from low-cost, high-grade gold production with a self-funded development pipeline spanning near-term mine life extension, advanced-stage project construction, and genuine exploration discoveries across three West African jurisdictions.The company operates the 100%-owned Segilola gold mine in Nigeria, producing 90,000–95,000 ounces annually at all-in sustaining costs below $1,000 per ounce. At current gold prices above $4,000 per ounce, Thor captures operating margins exceeding $3,000 per ounce, creating substantial free cash flow that funds quarterly dividends whilst simultaneously financing aggressive exploration and development programmes without equity dilution. Q3 2025 operational results demonstrated this financial strength, with production of 22,600 ounces generating approximately $70 million in revenue. Management's strategic decision to withhold 3,000 ounces for Q4 sale above $4,000 per ounce positions the company for potentially record quarterly financial performance. Thor has completely repaid its project debt, achieving a debt-free balance sheet that provides exceptional strategic flexibility for capital allocation decisions. This financial position distinguishes Thor from capital-constrained peers and enables the company to advance multiple projects simultaneously across different development stages.The Segilola operation represents Thor's immediate value creation opportunity through mine life extension. The company has deployed five drilling rigs exploring beneath the existing pit, systematically intersecting high-grade underground mineralisation averaging 5.5 grams per tonne (g/t) compared to open pit grades of just over 4 g/t. With all infrastructure capital expenditure already sunk and operational expertise established, every additional ounce discovered creates what management characterizes as "super ounces" requiring minimal incremental capital to extract. Thor targets an updated resource estimate in Q1 2026 whilst also pursuing satellite deposits within a 50-kilometre radius of the processing plant. The company plans a pilot mining operation in 2026 at one southern target, supplementing an existing stockpile containing over 44,000 ounces representing more than $175 million in contained gold value.Thor's Douta project in Senegal represents material near-term production growth, with a preliminary feasibility study weeks from completion. The project carries estimated capital costs of $250–$300 million, of which Thor will self-fund $150 million from operational cash flows. The remaining $100 million will be sourced through debt financing with Africa Finance Corporation, which financed Segilola and maintains an equity stake. Management targets first gold production in Q1 2028 following an investment decision expected in H1 2026, with the project featuring a larger resource base than Segilola and approximately 10 years of mine life that would materially increase Thor's consolidated production profile.Early-stage exploration success in Côte d'Ivoire provides genuine blue-sky discovery potential. At Guitry, 4,600 metres of drilling has delineated six mineralised lenses with high-grade intersections including 10 metres at 10 g/t across just 15% of an 8-kilometre by 5-kilometre geochemical footprint. The Marahui project has identified 8 kilometres of drill targets with surface rock chips returning 10–17 g/t. Both projects advance toward maiden resource estimates in H1 2026 through continuous drilling programmes funded entirely from internal cash generation.Thor's investment proposition centres on operational execution, financial strength, and portfolio diversification. The company's ability to generate substantial cash flows whilst advancing multiple growth opportunities without external capital requirements creates a differentiated risk-reward profile. Multiple near-term catalysts through 2026 include the Douta feasibility study release, Segilola resource update, Côte d'Ivoire maiden resources, construction decision-making, and continued operational cash generation supported by elevated gold prices and proven low-cost production capabilities.View Thor Exploration's company profile: https://www.cruxinvestor.com/companies/thor-explorations-ltdSign up for Crux Investor: https://cruxinvestor.com

See omnystudio.com/listener for privacy information.

L.A. County moves ahead with a ban on officers wearing masks on duty. Thousands of L.A. County residents are getting their medical debt erased. A federal judge has dismissed a lawsuit from Huntington Beach challenging the state’s sanctuary law. Plus, more from Evening Edition. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comThis LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autosVisit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support the show: https://laist.com

A bill that would overhaul how the federal government purchases software has found itself in a familiar place: moving forward in the House while awaiting Senate consideration with just a few weeks left in the congressional calendar. The Strengthening Agency Management and Oversight of Software Assets (SAMOSA) Act advanced out of the House Oversight and Government Reform Committee on Tuesday, teeing it up for a vote in the full chamber. The SAMOSA Act, which would direct federal agencies to assess their software licensing practices and streamline future IT buying decisions to avoid duplicative purchases, was reintroduced in the House in September following the Senate's move to do the same in July. The bill passed the House a year ago but stalled out in the upper chamber, despite backing from a host of software and IT trade groups, including the Computer & Communications Industry Association, the Alliance for Digital Innovation, NetChoice, OpenPolicy and the Software Information Industry Association. Congress has been trying to move forward with the SAMOSA Act since at least 2022. House Oversight Committee Chair James Comer, R-Ky., noted during Tuesday's markup that the current iteration of the SAMOSA Act is “identical” to what passed the chamber last year. In other news: The Small Business Administration may soon be forced to confront the flawed rollout of an online certification platform it launched late in the Biden administration.The House on Monday passed a bill that would require the SBA to implement nearly a dozen recommendations made in a Government Accountability Office report about the agency's Unified Certification Platform for small business contracting assistance. The lawmakers behind the SBA IT Modernization Reporting Act — Reps. Gil Cisneros, D-Calif., and Brian Jack, R-Ga. — believe the legislation will help the agency avoid various pitfalls that plagued the UCP, helping it better develop and manage digital projects going forward. The UCP project was launched in 2023 with the goal of easing small businesses' interactions with the SBA's contract assistance programs. But deployment of the platform was delayed and applications for certification were paused in August 2024. The UCP went live two months later, but according to the GAO, work to migrate data and secure the system was incomplete. House Small Business Committee Chair Roger Williams said before Monday's vote that the “failed … portal rollout resulted in delays, errors and cybersecurity risks, shutting out small businesses from the vital government contracting opportunities.” The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

Interview with Mark Petersen, Senior Geological Consultant of Wallbridge MiningOur previous interview: https://www.cruxinvestor.com/posts/wallbridge-mining-wm-updated-resource-will-delight-market-2169Recording date: 27th November 2025Wallbridge Mining is pursuing a calculated two-pronged approach across its Quebec gold assets, balancing near-term development at Fenelon with aggressive exploration at the Martiniere system. Mark Peterson, Senior Geological Consultant with over 40 years of experience, leads the geological strategy following his tenure at New Gold.At Fenelon, the company has fundamentally restructured its resource model, simplifying mineralized domains from over 100 discrete zones to 16 user-friendly envelopes. This redesign better aligns with the project's 40-meter drill spacing and creates practical targets for underground mining operations. The deposit features coarse visible gold throughout all rock types, supporting bench-scale metallurgical test results showing 30% initial gravity recovery and 96% total recovery—characteristics that could enable simpler processing and lower operating costs.The company's preliminary economic assessment incorporates existing underground infrastructure from a flooded historic pit, providing capital-efficient portal access. Despite higher upfront costs, Wallbridge selected dry-stack tailings to address both industry trends and site-specific challenges posed by Quebec's saturated glacial overburden terrain. Approximately one million ounces of resource remain excluded from the current mine plan, offering future expansion potential.At Martiniere, Peterson has pivoted to testing fundamental system scale rather than incremental resource growth. The exploration team employs aggressive 150-meter drill spacing across a two-kilometer strike length, rapidly covering prospective ground while accepting that subsequent infill will be required. First-principles structural remodeling identified 14 distinct fault structures along the Bug Lake deformation corridor, with recent drilling encountering mineralization including three meters at approximately seven grams per tonne half a kilometer from the Horsefly area.The critical next phase involves a 50,000-75,000 meter infill drilling program at Fenelon to convert inferred resources to indicated category, while a mineral inventory assessment at Martiniere will determine whether data supports the target of a two-million-ounce-plus system before committing to closer-spaced delineation drilling.View Wallbridge Mining's company profile: https://www.cruxinvestor.com/companies/wallbridge-miningSign up for Crux Investor: https://cruxinvestor.com

Short Summary: Dr. Holly Helbig and Dr. David Levine describe how they use SAA and other biomarkers to spot infection early, guide treatment, support biosecurity, and monitor horses in real time.Landing page copy: Acute phase proteins such as serum amyloid A (SAA) give veterinarians an early look at inflammation, infection, and how a horse responds to treatment. In this Equine Innovators episode, we dig into how SAA and other key biomarkers guide everyday decisions—from biosecurity on busy farms and showgrounds to managing postoperative cases, colic, and foal exams.Host Stephanie Church, editorial director at The Horse, talks with Dr. Holly Helbig of Zoetis and Dr. David Levine from the University of Pennsylvania's New Bolton Center about when they reach for SAA, how it compares with fibrinogen and white blood cell counts, and why serial testing often matters more than any single number. They share stall-side and hospital protocols, real-world case examples, and ways biomarker trends support smarter antimicrobial use and quarantine decisions.In this episode, Drs. Helbig and Levine discuss:What acute phase proteins are and how SAA reflects early inflammation in horsesHow fast SAA and fibrinogen rise and fall, and how that timing shapes testing plansWhen stallside SAA testing shines in ambulatory practice, at horse shows, and on the farmUsing SAA to help sort out joint flares vs. septic joints and guide post-surgical monitoringPractical cutoffs and patterns for foals, including how vaccination and IV plasma affect SAAWhere SAA fits into antimicrobial stewardship and cost-conscious biosecurity strategiesEmerging research and what might come next for biomarkers in equine practiceTune in to hear how two equine veterinarians lean on SAA and other biomarkers to clarify tough calls, support horse owners, and keep diagnostics and treatments on the right track.GUESTS AND LINKS – EPISODE 23:Host: Stephanie L. Church, editorial director at The Horse: Your Guide to Equine Health Care/TheHorse.com | @stephlchurch on Instagram | Email Stephanie (schurch@thehorse.com)Links: (SAA and other Biomarker resources from TheHorse.com) SAA: A Magic 8 Ball for Detecting Infection in Horses?, SAA: Infection Detection in Horses (Infographic), SAA Measurements Can Help Detect Surgical Implant Infection, Advances in Equine Infectious Disease DetectionGuest: Holly Helbig, DVM, joined Zoetis in 2023 as an equine technical services veterinarian. She is a graduate of The Ohio State University with a focus in lameness and sport horse medicine. Helbig was the official veterinarian for The World Equestrian Center Ohio; The Kentucky Horse Shows series; and various FEI competitions for 10 years prior to joining Zoetis. She also had an ambulatory practice serving patients...

Dr. Fernando Angarita sits down with Dorothy to talk about what drives his practice at Houston Methodist. From his start in Colombia to his commitment in Houston, Dr. Angarita centers every decision on building trust and supporting each woman’s choices. Every patient in his care gets respectful, individualized attention, no matter her circumstances. Learn more about Dr. Angarita HERE. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. What is oncolytic virotherapy and how does it relate to breast cancer treatment?2. How did Dr. Angarita end up practicing in Texas after training in different countries?3. Did Dr. Angarita always want to be a doctor, and what influenced his career choice?4. What drew Dr. Angarita to breast cancer surgery specifically?5. How has breast cancer surgery changed in recent years?6. Do most patients opt for breast reconstruction after surgery?7. What unique challenges do uninsured patients face regarding breast cancer?8. How does Dr. Angarita help empower patients during their breast cancer journey?9. What are the specific considerations when treating older women with breast cancer?10. How important is body image and cosmetic outcome to patients after breast cancer surgery? Timestamped Overview 00:00 Journey to Breast Surgical Oncology 05:42 Advancing Breast Cancer Treatment 06:53 "Advances in Breast Cancer Treatment" 10:28 Breast Cancer Treatment and Reconstruction 12:55 "Prioritizing Patient-Centered Care" 18:21 "Importance of Patient Questions" 21:30 Breast Cancer Risk in Older Age 25:01 Breast Surgery: Image and Options 27:59 Personalized Breast Cancer Care AdvancementsSee omnystudio.com/listener for privacy information.

Chris and Daniel unpack how AI-driven document processing has rapidly evolved well beyond traditional OCR with many technical advances that fly under the radar. They explore the progression from document structure models to language-vision models, all the way to the newest innovations like Deepseek-OCR. The discussion highlights the pros and cons of these various approaches focusing on practical implementation and usage.Featuring:Chris Benson – Website, LinkedIn, Bluesky, GitHub, XDaniel Whitenack – Website, GitHub, XSponsors:Shopify – The commerce platform trusted by millions. From idea to checkout, Shopify gives you everything you need to launch and scale your business—no matter your level of experience. Build beautiful storefronts, market with built-in AI tools, and tap into the platform powering 10% of all U.S. eCommerce. Start your one-dollar trial at shopify.com/practicalaiFabi.ai - The all-in-one data analysis platform for modern teams. From ad hoc queries to advanced analytics, Fabi lets you explore data wherever it lives—spreadsheets, Postgres, Snowflake, Airtable and more. Built-in Python and AI assistance help you move fast, then publish interactive dashboards or automate insights delivered straight to Slack, email, spreadsheets or wherever you need to share it. Learn more and get started for free at fabi.aiFramer – Design and publish without limits with Framer, the free all-in-one design platform. Unlimited projects, no tool switching, and professional sites—no Figma imports or HTML hassles required. Start creating for free at framer.com/design with code `PRACTICALAI` for a free month of Framer Pro.Upcoming Events: Register for upcoming webinars here!

Breast cancer often surfaces in the moments people don't talk about—appointments pushed months out, mixed messages from providers, and the quiet fear that something serious might be brushed aside.In this episode, Michael Desrosiers sits down with flight attendants Kimberly Burckhalter and Derrian Aversa, whose diagnoses are decades apart yet shaped by the same need to push for answers. Kim recalls finding a lump in her early thirties and refusing to accept reassurances that didn't feel right. Derrian explains how today's advanced treatments still sit behind layers of scheduling delays, limited staffing, and constant follow-up calls.Their conversation asks the harder questions. Why do some patients move quickly through care while others face roadblocks at every step? How much do geography, staffing shortages, and insurance policies determine the path long before treatment begins? And what kind of support truly helps when fear takes over and details become hard to process?Together, they offer a clear, compassionate reminder: trust what your body is telling you, speak up early, and keep people close who help you stay steady when the system makes everything harder than it should be.Episode Breakdown:00:00 Breast Cancer Awareness01:00 Early Detection and Kim's Diagnosis04:16 Derrian's Delayed Care and HER2-Positive Results09:48 Why Support Systems Matter10:37 Flight Attendant Risk Factors15:16 Healthcare Delays and Systemic Barriers20:36 Insurance Challenges and Access to Treatment30:32 Advances in Breast Cancer Treatment35:00 Self-Advocacy and Early ActionLinksVisit the Cuckoo4Politics websiteFollow Cuckoo4Politics on InstagramFollow Cuckoo4Politics on FacebookFollow Cuckoo4Politics on TikTokFollow Cuckoo4Politics on BlueskyPodcast production and show notes provided by HiveCast.fm

Advances in molecular diagnostics are reshaping how cancer is detected, monitored, and treated, and liquid biopsy is becoming central to that progress. This simple blood draw can reveal key tumor biology at diagnosis and over time, providing timely insight and guiding more precise decisions throughout a patient's journey. Clinicians now face an important challenge: knowing what is actionable today and what is coming next so more patients can benefit from the promise of these advances.As we kick off Season 7, host and patient advocate Karan Cushman expands this season's focus on Bringing Precision Medicine to Everyone with a deeper look inside the science of liquid biopsy. The conversation features two leaders shaping the field: Dr. Christian Rolfo, Division Director of Medical Oncology at The James Comprehensive Cancer Center at Ohio State University, and Dr. Roberto Borea, Medical Oncologist and emerging investigator from the Rolfo Lab.Together, they break down the scientific momentum driving liquid biopsy forward, including tumor fraction, MRD-guided treatment strategies, resistance monitoring, fragmentomics, and the expanding frontier of early detection. They also discuss the barriers that continue to slow broader adoption, such as assay variability, limited standardization, reimbursement gaps, and operational challenges in community settings.In this episode, we cover:• How tumor fraction is emerging as a meaningful real-time biomarker• Where MRD-driven escalation and de-escalation strategies are heading• The current promise and limitations of early detection and MCED testing• What is required to standardize liquid biopsy across reporting, workflows, and clinical trialsEpisode 70 offers a clear look at the advances researchers are helping drive right now and what these developments could mean for clinicians, laboratories, and patients in the near future.This conversation builds on episode 69 with Dr. Kashyap Patel, who introduced the foundations of liquid biopsy and its role in accelerating treatment decisions. Combined, these two episodes offer clinicians and patients an overview of where the science and real-world applications stand now and where the field is headed next.

Short Summary: Dr. Holly Helbig and Dr. David Levine describe how they use SAA and other biomarkers to spot infection early, guide treatment, support biosecurity, and monitor horses in real time.Landing page copy: Acute phase proteins such as serum amyloid A (SAA) give veterinarians an early look at inflammation, infection, and how a horse responds to treatment. In this Equine Innovators episode, we dig into how SAA and other key biomarkers guide everyday decisions—from biosecurity on busy farms and showgrounds to managing postoperative cases, colic, and foal exams.Host Stephanie Church, editorial director at The Horse, talks with Dr. Holly Helbig of Zoetis and Dr. David Levine from the University of Pennsylvania's New Bolton Center about when they reach for SAA, how it compares with fibrinogen and white blood cell counts, and why serial testing often matters more than any single number. They share stall-side and hospital protocols, real-world case examples, and ways biomarker trends support smarter antimicrobial use and quarantine decisions.In this episode, Drs. Helbig and Levine discuss:What acute phase proteins are and how SAA reflects early inflammation in horsesHow fast SAA and fibrinogen rise and fall, and how that timing shapes testing plansWhen stallside SAA testing shines in ambulatory practice, at horse shows, and on the farmUsing SAA to help sort out joint flares vs. septic joints and guide post-surgical monitoringPractical cutoffs and patterns for foals, including how vaccination and IV plasma affect SAAWhere SAA fits into antimicrobial stewardship and cost-conscious biosecurity strategiesEmerging research and what might come next for biomarkers in equine practiceTune in to hear how two equine veterinarians lean on SAA and other biomarkers to clarify tough calls, support horse owners, and keep diagnostics and treatments on the right track.GUESTS AND LINKS – EPISODE 23:Host: Stephanie L. Church, editorial director at The Horse: Your Guide to Equine Health Care/TheHorse.com | @stephlchurch on Instagram | Email Stephanie (schurch@thehorse.com)Links: (SAA and other Biomarker resources from TheHorse.com) SAA: A Magic 8 Ball for Detecting Infection in Horses?, SAA: Infection Detection in Horses (Infographic), SAA Measurements Can Help Detect Surgical Implant Infection, Advances in Equine Infectious Disease DetectionGuest: Holly Helbig, DVM, joined Zoetis in 2023 as an equine technical services veterinarian. She is a graduate of The Ohio State University with a focus in lameness and sport horse medicine. Helbig was the official veterinarian for The World Equestrian Center Ohio; The Kentucky Horse Shows series; and various FEI competitions for 10 years prior to joining Zoetis. She also had an ambulatory practice serving patients...

Welcome to the Social-Engineer Podcast: The Doctor Is In Series – where we will discuss understandings and developments in the field of psychology.   In today's episode, Chris and Dr. Abbie explore cognitive dissonance, focusing on its impact on self-concept and emotional regulation. They discuss how dissonance occurs when actions conflict with core beliefs, creating psychological tension. Emphasizing self-awareness and reflection, they warn against rationalizing harmful behaviors and highlight the importance of embracing discomfort for personal growth and identity development. [Dec 1, 2025]     00:00 - Intro 00:26 - Dr. Abbie Maroño Intro 00:43 - Intro Links -          Social-Engineer.com - http://www.social-engineer.com/ -          Offensive Security Vishing Services - https://www.social-engineer.com/offensive-security/vishing/ -          Offensive Security SMiShing Services - https://www.social-engineer.com/offensive-security/smishing/ -          Offensive Security Phishing Services - https://www.social-engineer.com/offensive-security/smishing/ -          Call Back Phishing - https://www.social-engineer.com/offensive-security/call-back-phishing/ -          Adversarial Simulation Services - https://www.social-engineer.com/offensive-security/adversarial-simulation/ -          Social Engineering Risk Assessments - https://www.social-engineer.com/offensive-security/social-engineering-risk-assessment/ -          Social-Engineer channel on SLACK - https://social-engineering-hq.slack.com/ssb -          CLUTCH - http://www.pro-rock.com/ -          innocentlivesfoundation.org - http://www.innocentlivesfoundation.org/                 02:40 - The Topic of the Day: What is Cognitive Dissonance? 05:53 - A Threat to Self-Concept 07:49 - Commitment to Consistency 09:51 - Freedom to Choose 10:51 - Changing Beliefs 14:19 - Trying to Escape 18:21 - Going From Bad to Worse 21:53 - Self-Awareness is Key! 24:55 - Growth Hurts 28:49 - Everything, Not All At Once 29:43 - It's Not A Flaw 31:11 -  Wrap Up 31:36 - Next Month's Topic: Is Everyone a Psychopath? 31:52 - Outro -          www.social-engineer.com -          www.innocentlivesfoundation.org   Find us online: -          LinkedIn: linkedin.com/in/dr-abbie-maroño-phd -          Instagram: @DoctorAbbieofficial -          LinkedIn: linkedin.com/in/christopherhadnagy     References: Aronson, E. (1969). The theory of cognitive dissonance: A current perspective. Advances in Experimental Social Psychology, 4, 1–34. Bandura, A. (1999). Moral disengagement in the perpetration of inhumanities. Personality and Social Psychology Review, 3(3), 193–209. Brehm, J. W. (1956). Postdecision changes in the desirability of alternatives. Journal of Abnormal and Social Psychology, 52(3), 384–389. Festinger, L. (1957). A theory of cognitive dissonance. Stanford University Press. Kunda, Z. (1990). The case for motivated reasoning. Psychological Bulletin, 108(3), 480–498. Schumann, K., & Dweck, C. S. (2014). Who accepts responsibility for their transgressions? Personality and Social Psychology Bulletin, 40(12), 1608–1622. Sherman, D. K., & Cohen, G. L. (2006). The psychology of self-defense: Self-affirmation theory. Advances in Experimental Social Psychology, 38, 183–242. Staub, E. (1990). Moral exclusion, personal goal theory, and extreme destructiveness. Journal of Social Issues, 46(1), 47–64. Steele, C. M. (1988). The psychology of self-affirmation: Sustaining the integrity of the self. Advances in Experimental Social Psychology, 21, 261–302. van Veen, V., Krug, M. K., Schooler, J. W., & Carter, C. S. (2009). Neural activity predicts attitude change in cognitive dissonance. Nature Neuroscience, 12(11), 1469–1474.

New legislation could expand milk choices in schools and influence California's dairy sector.

Interview with Sam Hartmann, VP Exploration, and Dev Randhawa, Chairman & CEO, of F3 Uranium Corp.Our previous interview: https://www.cruxinvestor.com/posts/f3-uranium-tsxvfuu-billion-dollar-discovery-team-strikes-again-in-worlds-best-uranium-district-7874Recording date: 27th November 2025F3 Uranium Corp. (TSXV: FUU) has completed a $20 million financing to fund a year-long drilling campaign at its Tetra Zone discovery in Saskatchewan's Athabasca Basin. The financing, which included $15 million in flow-through funds, brings the company's treasury to $30 million and eliminates near-term dilution pressure as the exploration program advances.CEO Dev Randhawa explained the strategic shift toward Tetra Zone, which has emerged as the company's primary focus after the JR Zone failed to grow as anticipated. Despite JR's promising initial indicators, including peak grades of 4.5 meters at 50% uranium along a large conductor, the system has not delivered the expansion investors expected. Tetra Zone, by contrast, shows significantly greater potential with 60 meters of mineralization-three times what JR produced-sits just 12 kilometers from the Arrow and Triple R deposits along an apparent productive geological trend.Recent drilling results support management's confidence in the discovery. The most recent hole intersected mineralization in a 15-meter step-out, with scintillometer readings exceeding 10,000 counts per second across 30+ meters. Chief Geologist Sam Hartmann estimates a 2.3-meter high-grade interval "will be well over a percent" when laboratory assays are returned. This successful step-out confirms both continuity and the geological model's predictive capability.The technical understanding of Tetra has evolved considerably from initial interpretations. Unlike typical Athabasca deposits controlled by graphitic conductors, Tetra appears to be shear-zone-controlled, with mineralization in micaceous structures that generate weaker geophysical signatures. This realization explains why early drilling repeatedly intersected mineralization at unexpected depths and has enabled more confident targeting going forward.F3's systematic approach involves methodical 25-50-100 meter step-outs to balance resource definition with expansion testing. With an experienced discovery team that previously found Waterbury and contributed to the Triple R discovery (sold for approximately $1 billion), the company is positioned to methodically test whether Tetra can join the ranks of significant Athabasca Basin uranium deposits. Regular drilling results are expected throughout 2026 as the delineation program progresses.View F3 Uranium's company profile: https://www.cruxinvestor.com/companies/f3-uranium-corpSign up for Crux Investor: https://cruxinvestor.com

I'm so excited to share this special episode of "FertiliTEA with Dr. D," where I had the honor of joining my dear friend and colleague, Dr. D, to talk all things fertility. As the Egg Whisperer, I'm passionate about helping people on their journey to parenthood, and it was a joy to connect with Dr. D: someone who shares my dedication and obsession for supporting patients through every step of their fertility journey. Together, we dove into the science, the stories, and the hope that drives us both in this field. In this episode, we cover: Why "perfect" embryos don't always lead to pregnancy, and what factors might be at play The latest thinking on supplements for egg and sperm quality, including CoQ10, NAD, and rapamycin How genetics, epigenetics, and the uterine environment impact implantation and pregnancy The importance of personalized fertility care, including testing for endometriosis, endometritis, and the uterine microbiome The role of weight, nutrition, and GLP-1 medications in fertility and pregnancy outcomes Advances in sperm DNA fragmentation testing and embryo selection The emotional, spiritual, and practical realities of fertility treatment, including the option of gestational carriers Resources: American Society of Reproductive Medicine (ASRM): https://www.asrm.org/ Information on supplements discussed: CoQ10, NAD+, Rapamycin Pre-implantation genetic testing (PGT-A): https://www.asrm.org/topics/topics-index/preimplantation-genetic-testing/ Endometrial receptivity and microbiome testing: ERA Test, EMMA/ALICE Test If you have questions or want to learn more, don't hesitate to reach out. Thank you for listening, and thank you to Dr. D for having me on the show! Would you like to learn more about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, December 15th, 2025 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Are you up to date on emerging pharmacologic therapies transforming obesity and type 2 diabetes care? Credit available for this activity expires: 11/28/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/advances-pharmacologic-management-obesity-expert-digest-2025a1000v94

Opus 4.5 showcases Anthropic's expertise in building robust context-handling models. The memory redesign improves both short- and long-term retention. This episode covers the full upgrade.Get the top 40+ AI Models for $20 at AI Box: ⁠⁠https://aibox.aiAI Chat YouTube Channel: https://www.youtube.com/@JaedenSchaferJoin my AI Hustle Community: https://www.skool.com/aihustleSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Lipoprotein(a) Testing Trends in the United States 2015-2024: An Analysis of 300 Million Individuals.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Multicenter Prospective Assessment of Coronary Microvascular Dysfunction: Primary Results of the FlowLab Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Implications of Preoperative hs-cTnT in Elective Coronary Artery Bypass Grafting.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Predictive Models Aid Prognostication: Secondary Analysis Integrating Model and Physician Prognostic Estimates in Heart Failure.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Elevated Lipoprotein(a) Independently Increases Risk for Short-Term Atherosclerotic Cardiovascular Events in Machine Learning Predictive Models.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Educational Attainment as the Primary Socioeconomic Determinant of Heart Failure: A Multivariable Mendelian Randomization Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Long-Term Implantable Cardioverter Defibrillator Lead Dysfunction After Left Ventricular Assist Device Implantation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Gender Differences in Barriers to Academic Cardiovascular Careers in North America.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Unfavorable Social Determinants of Health and Obesity: A Double Jeopardy for Premature Mortality.

The Padres hired their new hitting and bench coaches, and neither are impressive names. SDFC beat Minnesota 1-0 to advance to the MLS Western Finals. SDSU got blasted by #7 Michigan in Vegas. Craig Dado joins the show to pick NFL Week 13 winners.Support the show: http://kaplanandcrew.com/See omnystudio.com/listener for privacy information.

00:00 Intro01:03 Japan Advances Air Defense Systems, Deployment Near Taiwan03:11 Xi Emphasizes Taiwan, White House Remains Silent03:48 U.S. Nuclear-Powered Carriers Deployed Near China05:08 U.S., China Held Maritime Security Talks in Hawaii05:57 Lutnick: Trump Weighs Nvidia AI Chip Sales to China07:21 How the Nexperia Chip Crisis Upended Auto Supply Chains09:45 UK Moves to Cut Reliance on China's Rare Earths12:06 U.S., EU to Diversify Trade Relations13:34 China Absent from New Field of Biocomputing: Jordan

Wound care is an important part of recovery for patients with neurogenic bladder undergoing complex lower urinary tract surgery. In this episode, Madison Hughes talks with Dr. Kyle Rove and Dr. Kelly Harris, pediatric urologists at Children's Hospital Colorado, about the latest advancements in wound care and what patients can expect along the way. 

In today's episode, we had the pleasure of speaking with Daniel Spratt, MD, chair and professor in the Department of Radiation Oncology at Case Western Reserve University School of Medicine and a member of the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr Spratt discussed key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer, including how advances in molecular imaging, evolving systemic therapy options, and the integration of next-generation androgen deprivation therapy (ADT) are reshaping treatment recommendations across localized, recurrent, and advanced disease settings.

The Padres hired their new hitting and bench coaches, and neither are impressive names. SDFC beat Minnesota 1-0 to advance to the MLS Western Finals. SDSU got blasted by #7 Michigan in Vegas. Craig Dado joins the show to pick NFL Week 13 winners.Support the show: http://kaplanandcrew.com/See omnystudio.com/listener for privacy information.

Join us LIVE on Loud & Proud Orlando!

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a significant advancement in the therapeutic landscape for this type of cancer, offering new hope to patients who have had limited treatment options. The combination of these two therapies underscores the growing trend of integrating multiple mechanisms of action to tackle complex diseases like cancer more effectively. It also highlights the potential of combination therapies to provide enhanced clinical benefits by leveraging different therapeutic targets.In another notable development, Merck's partner Kelun announced successful Phase 3 trial results for an antibody-drug conjugate combined with Keytruda in treating PD-L1-positive non-small cell lung cancer (NSCLC). The trial results demonstrated statistically significant improvements in progression-free survival compared to Keytruda alone. This finding reinforces the expanding role of antibody-drug conjugates in oncology and emphasizes the importance of biomarker-driven therapies in personalizing cancer treatment. These advancements reflect a broader industry shift towards precision medicine, which aims to improve patient outcomes by tailoring treatments based on individual patient profiles.Meanwhile, Novo Nordisk experienced setbacks as its shares fell nearly 9% following two unsuccessful Phase 3 trials of semaglutide for Alzheimer's disease. Despite these disappointing results, this outcome highlights the persistent challenges and complexities inherent in developing therapies for neurodegenerative diseases—areas where unmet needs remain substantial. The market's reaction reflects investor sensitivity to clinical trial outcomes, particularly in high-stakes areas like Alzheimer's where breakthroughs are eagerly anticipated.Switching gears to AstraZeneca, the company is making a strategic move by expanding its manufacturing capabilities with a $2 billion investment in Maryland. This expansion reflects an ongoing trend among pharmaceutical companies to enhance their production infrastructure, driven by increasing demand for biologics and complex therapeutics. Such investments are crucial for supporting large-scale production needs and ensuring robust supply chains that are essential for meeting global health demands.In regulatory news, a collective letter from biotech CEOs addressed to FDA director Marty Makary has raised concerns about regulatory stability in the U.S., with 82% of biopharma respondents expressing apprehension over the FDA's ability to function predictably. This plea underscores how regulatory volatility can hinder innovation and emphasizes the importance of consistent policies that support long-term research and development efforts.In clinical trial updates, Bayer's oral FXIa inhibitor asundexian has shown promise in reducing stroke risk during Phase 3 trials. These findings revive interest in FXIa inhibitors as potentially blockbuster drugs after previous setbacks in this class. This development illustrates ongoing efforts to identify novel anticoagulant therapies that balance efficacy and safety, offering new hope for improved therapeutic options.Now turning our attention to Johnson & Johnson's recent setback with their anti-tau antibody posdinemab in a phase 2 trial targeting Alzheimer's disease. The trial was unable to demonstrate a significant slowing of clinical decline, leading JSupport the show

In today's episode,filmed live at the 43rd Annual CFS Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with breast cancer experts Kamel Abou Hussein, MD, and Victoria Rizk, MD, about the rapidly evolving therapeutic landscape in breast cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Abou Hussein is co-director of the Janet Knowles Breast Cancer, director of Breast Medical Oncology, and director of Breast Cancer Clinical Trials at Cooper University Health Care; as well as an assistant professor of medicine at Cooper Medical School of Rowan University in Camden, New Jersey. Dr Rizk is a medical oncologist at Tampa General Hospital Cancer Institute in Florida.

APAC stocks mostly firmer following the Wall St. handover, though China was mixed amid reports of Trump selling NVIDIA chips to China.Fed's Collins says she has not made up her mind on December. Treasury Secretary Bessent said prices are getting better.DXY contained, EUR/USD bounced from 1.15, Cable rangebound, USD/JPY firmer but limited in holiday trade.USTs and Bunds contained after the moves seen on Friday; Crude is uneventful, XAU continues to fade.US' Rubio said good progress had been made re. Ukraine, and none of the outstanding issues are insurmountable.Looking ahead, highlights include German Ifo (Nov), US National Activity Index (Oct), Dallas Fed Manufacturing Index (Nov), Speakers including ECB's Cipollone, Elderson & Lagarde, Supply from the US.Click for the Newsquawk Week Ahead.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Blood-based colorectal cancer screening is entering a new era with FDA-approved and emerging tests like Shield and Simple Screen. Alongside updated stool-based options such as Cologuard Plus and CRC-PREVENT, clinicians now have a broader landscape of noninvasive tools to consider and discuss with their patients. Joining Dr. Peter Buch to talk about current recommendations and potential future directions for colorectal cancer screening is Dr. Aasma Shaukat. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor of Population Health at NYU Grossman School of Medicine, as well as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health. She's also a co-author of a recent review on blood tests for colorectal cancer.

CONTINUED HEADLINE: Private Space Advances (Blue Origin, Rocket Lab) Challenge NASA SLS, EU Space Law CriticizedGUEST: Bob Zimmerman

Broadcast from KSQD, Santa Cruz on 11-20-2025: Dr. Dawn discusses GLP-1 inhibitors like Zepbound and semaglutide showing unexpected benefits for addiction treatment beyond diabetes and weight loss. Patients in rehab report these drugs mute cravings for alcohol, cocaine, and cigarettes. Multiple studies show reduced substance abuse rates in users, with VA and NIH conducting trials examining brain activity and responses to triggers. With 80,000 annual drug overdose deaths and 48 million Americans having substance abuse disorders, these medications may revolutionize addiction treatment by dampening brain reward circuitry, though costs threaten healthcare budgets. A Stanford twin study found those twins assigned a vegan diet had substantially lower cholesterol, insulin, and body weight compared to their omnivore twins after several months, with LDL dropping 15mg, four pounds more weight loss, and 20% lower insulin. Dr. Dawn explains how a fungal disease decimating Central American frog populations caused 500% malaria increases in some areas. The fungus kills frogs by blocking skin electrolytes until hearts stop, eliminating tadpoles that eat mosquito larvae. Ecosystem collapses followed with algae blooms and snake population drops. She provides other examples showing how species losses affect human health, emphasizing the "one health" movement recognizing ecosystem health as fundamental to human wellbeing. An Australian study found people aged 70+ who listen to or play music regularly had 39% lower dementia rates, though causation remains uncertain. Princeton research shows music activates multiple brain regions simultaneously. Learning instruments increases gray matter, and musical memory remains intact in advanced dementia since it's stored separately from other memories. A caller discusses how modern screen-based activities provide less multisensory engagement than past social experiences like dances. Another caller describes Grover's disease causing persistent itchy skin with no known cause. Dr. Dawn recommends an elimination diet removing common allergens for one month, then reintroducing individually to identify food sensitivities triggering immune responses. Dr. Dawn explains xenotransplantation advances with genetically edited pigs beginning full-scale kidney transplant trials. Companies use CRISPR to disable genes causing immune rejection and insert human genes promoting immune tolerance. With only 10% of global kidney patients receiving organs, these could provide unlimited supply. Other innovations include kidneys with thymus tissue to teach immune tolerance and external pig liver systems as transplant bridges. She concludes noting research showing female dogs remember and prefer humans who demonstrate competence at tasks, while male dogs show no preference.

11-20-25 - Door Dash Driver Facing Charges After Taking Pics Of Pantsless Man Who Answered Door - 94yo Smokey Robinson Being Accused Of Unwanted Sexual Advances Making Us Wonder How You Can't Defend Against a 90yo ManSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

11-20-25 - Door Dash Driver Facing Charges After Taking Pics Of Pantsless Man Who Answered Door - 94yo Smokey Robinson Being Accused Of Unwanted Sexual Advances Making Us Wonder How You Can't Defend Against a 90yo ManSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“We have made great progress in treating lung cancer, but we still have a long way to go,” said Triparna Sen, PhD, a James scientist who specializes in translational research to better understand and treat lung cancer. Listen as Sen explains the biology and differences between the two different types of lung cancer (non-small cell and the less common, but more aggressive small cell); the latest treatments, including immunotherapy; and how a better understanding of the biology of cancer cells has led to improved drugs (such as immunotherapy) and better outcomes for patients. She also described how cancer cells are able to adapt and transform their biology and actually become “a new form of cancer.” Once this happens, over the course of several months, the immunotherapy drugs “no longer recognize the tumor.”

As President Trump met with Saudi Crown Prince Mohammed Bin Salman at the White House on Tuesday, the House overwhelmingly approved the Epstein File Transparency Act, sending it to the Senate for consideration.  FOX News Contributor and Outkick Columnist Mary Katherine Ham, FOX News Senior Political Analyst Juan Williams, and FOX News Correspondent Mark Meredith break down the latest developments surrounding the Epstein files. Later, they examine the potential impact of advanced U.S. warplane sales to Saudi Arabia as Israel and Gaza enter a pivotal phase in peace negotiations. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Lung cancer is the third most common cancer in the U.S. It's caused by harmful cells in your lungs growing unchecked. Treatments include surgery, chemotherapy, immunotherapy, radiation and targeted drugs. Screening is recommended if you're at high risk. Advances in treatments have caused a significant decline in lung cancer deaths in recent years. ​ Lung cancer is a disease caused by uncontrolled cell division in your lungs. Your cells divide and make more copies of themselves as a part of their normal function. But sometimes, they get changes (mutations) that cause them to keep making more of themselves when they shouldn't. Damaged cells dividing uncontrollably create masses, or tumors, of tissue that eventually keep your organs from working properly. Lung cancer is the name for cancers that start in your lungs — usually in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that start in other places and move to your lungs are usually named for where they start (your healthcare provider may refer to this as cancer that's metastatic to your lungs). ​ There are many cancers that affect the lungs, but we usually use the term "lung cancer" for two main kinds: non-small cell lung cancer and small cell lung cancer.  Other types of cancer can start in or around your lungs, including lymphomas (cancer in your lymph nodes), sarcomas (cancer in your bones or soft tissue) and pleural mesothelioma (cancer in the lining of your lungs). These are treated differently and usually aren't referred to as lung cancer.  (CREDITS: Cleveland Clinic)

President Ahmed al-Sharaa meets Donald Trump in Washington, the first White House visit for a Syrian president. Can Trump bring the war torn country into America's orbit? Plus, Russia makes gains in Ukraine's east. How will it affect Trump's negotiations to settle the war? Learn more about your ad choices. Visit megaphone.fm/adchoices